TherapeuticsMD Announces $125 Million Offering of Common Stock

BOCA RATON, Fla.–(BUSINESS WIRE)–TherapeuticsMD, Inc. (NYSE MKT: TXMD) today announced the launch of an
underwritten public offering of $125 million of shares of its common
stock. TherapeuticsMD also expects to grant the underwriters a 30-day
option to purchase up to an additional 15% of the shares of common
stock. All of the shares in the offering are to be sold by
TherapeuticsMD. The offering is subject to market conditions, and there
can be no assurance as to whether or when the offering may be completed,
or as to the actual size or terms of the offering.

Goldman, Sachs & Co. and Cowen and Company are acting as joint
bookrunning managers for the offering. Stifel is acting as joint lead
manager for the offering and Guggenheim Securities is acting as
co-manager for the offering.

TherapeuticsMD intends to use a majority of the proceeds of the offering
to fund commercialization activities for TX-004HR, its applicator-free
vaginal estradiol softgel drug candidate, for other research, clinical
trials, clinical formulation and development and for working capital and
general corporate purposes.

TherapeuticsMD has filed a shelf registration statement on Form S-3,
including a preliminary prospectus supplement and accompanying
prospectus, with the Securities and Exchange Commission (the “SEC”),
relating to the public offering of the shares of common stock described
above. Before buying any shares of TherapeuticsMD’s common stock in the
offering, you should carefully read the preliminary prospectus
supplement and the accompanying prospectus, together with the
information incorporated therein. These documents contain important
information that you should consider when making your investment
decision. TherapeuticsMD’s SEC filings are available to the public from
the SEC’s website at www.sec.gov.
When available, copies of the preliminary prospectus supplement and the
accompanying prospectus relating to these securities may also be
obtained by contacting Goldman, Sachs & Co., Prospectus Department, 200
West Street, New York, NY 10282-2198, by calling (866) 471-2526 or by
emailing prospectus-ny@ny.email.gs.com;
or Cowen and Company, LLC at c/o Broadridge Financial Services, 1155
Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or
by phone (631) 274-2806 / Fax (631) 254-7140.

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA™ technology, TherapeuticsMD is developing advanced hormone
therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes.
The company’s clinical development pipeline includes two phase 3
products. The company also manufactures and distributes branded and
generic prescription prenatal vitamins as well as over-the-counter
vitamins under the vitaMedMD® and BocaGreenMD® brands.

Forward Looking Statements

This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that TherapeuticsMD
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties, many of which are outside of the
company’s control. These forward-looking statements are subject to risks
and uncertainties that may cause actual results to differ materially,
including the risks and uncertainties associated with market conditions,
the satisfaction of customary closing conditions related to the
offering, risks and uncertainties associated with TherapeuticsMD’s
business and finances in general and other risks described in the
sections titled “Risk Factors” in TherapeuticsMD’s filings with the SEC,
including its most recent Annual Report on Form 10-K and other filings
with the SEC.

Contacts

TherapeuticsMD, Inc.
Dan Cartwright, 561-961-1900
Chief
Financial Officer
Dan.Cartwright@TherapeuticsMD.com

Alrededor de la web